Deriving therapies for children with primary CNS tumors using pharmacokinetic modeling and simulation of cerebral microdialysis data.
The treatment of children with ependymoma and CNS tumors continues to be a challenge despite recent advances in technology and diagnostics. In this overview, St. Jude Children’s Research Hospital describes their approach for identifying and evaluating active anticancer drugs through a process that enables rational translation from the lab to the clinic. This approach involves performing extensive systemic (plasma) and target site (CNS tumor) pharmacokinetic studies. They examined two FDA approved drugs, simvastatin and pemetrexed, as candidates for new therapies for pediatric CNS tumors.
Read the PubMed Article, click here.